Document Detail

Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
MedLine Citation:
PMID:  17906864     Owner:  NLM     Status:  MEDLINE    
Patients with presumed non-obstructive BPH (Q (max )>or= 15 ml/s) treated with tolterodine ER 4 mg/day for OAB symptoms, alone or added to unsuccessful alpha-blocker treatment of >or=6 weeks duration, were observed for 12 weeks in a non-interventional study to generate real-life efficacy and safety data. Patients completed the IPSS, the OAB-q and a 2-day micturition diary at baseline and 12 weeks. PVR was determined sonographically. Seven hundred and forty one patients were analysed. Mean PVR did not increase (25.4 +/- 26.5 vs. 29.3 +/- 30.9 ml at baseline). AUR requiring catheterization occurred in two patients, acute UTI in four patients. Median IPSS total scores decreased from 17 to 10, IPSS QoL scores from 4 to 2, OAB-q symptom bother scores from 50.0 to 22.5 and OAB-q HRQL scores increased from 59.2 to 81.6. In men with OAB symptoms and presumed non-obstructive BPH, tolterodine ER provided considerable symptomatic and QoL improvements with a low risk of AUR, acute UTI, or increased PVR.
K Höfner; M Burkart; G Jacob; U Jonas
Related Documents :
7541194 - The importance of the prostate weight in transurethral microwave thermotherapy.
18937594 - Bilateral nerve-sparing extraperitoneal visual laser ablation radical prostatectomy: po...
10411044 - Transurethral thermotherapy for benign prostatic hyperplasia significantly decreases in...
1693454 - Evaluation of flow electromyography in patients with benign prostatic hyperplasia.
12150294 - Long-term results of the bentall operation versus separate replacement of the ascending...
19042044 - Statin therapy shortens qtc, qtcd, and improves cardiac function in patients with chron...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-09-29
Journal Detail:
Title:  World journal of urology     Volume:  25     ISSN:  0724-4983     ISO Abbreviation:  World J Urol     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-13     Completed Date:  2008-01-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8307716     Medline TA:  World J Urol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  627-33     Citation Subset:  IM    
Urologische Klinik, Evangelisches Krankenhaus Oberhausen, Virchowstrasse 20, 46047 Oberhausen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Benzhydryl Compounds / administration & dosage*,  adverse effects
Cresols / administration & dosage*,  adverse effects
Delayed-Action Preparations
Middle Aged
Muscarinic Antagonists / administration & dosage*,  adverse effects
Phenylpropanolamine / administration & dosage*,  adverse effects
Prostatic Hyperplasia / drug therapy*,  psychology
Quality of Life
Regression Analysis
Severity of Illness Index
Treatment Outcome
Urinary Bladder, Overactive / drug therapy*,  psychology
Urinary Incontinence, Urge / drug therapy,  psychology
Reg. No./Substance:
0/Benzhydryl Compounds; 0/Cresols; 0/Delayed-Action Preparations; 0/Muscarinic Antagonists; 124937-51-5/tolterodine; 14838-15-4/Phenylpropanolamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The signal transduction pathways controlling in planta tuberization in potato: an emerging synthesis...
Next Document:  Intracranial hypotension in a girl with Marfan syndrome: case report and review of the literature.